Efficacy and safety of once weekly semaglutide 2·[amount hidden] for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial

What Was Tested

This randomized controlled trial paper looks at Semaglutide.

For the Mandarin, Portuguese and South Korean translations of the abstract see Supplementary Materials section.

Who Took Part

PubMed indexes the participants as adults.

This randomised phase 3a, double-blind multicentre controlled trial (STEP 7) recruited participants from 23 hospitals and trial centres in China, Hong Kong, Brazil, and South Korea.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Semaglutide could be set against what happens without it.

More than one site took part, so the participants came from several places.

Randomisation was done in blocks of six with an interactive web response system and was stratified by diagnosis of type 2 diabetes.

This study is registered with ClinicalTrials.gov, NCT04251156, and is now complete.

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 2, East Asian People, Glucagon-Like Peptides, Hypoglycemic Agents, Obesity, Overweight and Semaglutide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (The lancet. Diabetes & endocrinology), a journal based in England.

More context: the Semaglutide compound page.